RISW2025
Back to the program
Parallel

PS47: Stat Leadership at Every Level: Embracing the Trends of Innovation (sponsored by the Biopharmaceutical Statistics Leadership Consortium)

Fri, Sep 26, 1:30 PM - 2:45 PM Room Brookside C Bethesda North Marriott Hotel & Conference Center
Ning LengOrganizerNing LengChair

About this session

In an era where artificial intelligence, digital technologies, and diverse data types are rapidly transforming the pharmaceutical landscape, statisticians often find themselves navigating a complex and overwhelming array of innovations. This surge presents both challenges and opportunities to integrate new methodologies without losing sight of the critical thinking and analytical rigor that define our profession. In this session, Supported by the Biopharma Statistics Leadership Consortium (BSLC), we plan to bring together four senior leaders from pharmaceutical data science organizations and leaders from health authorities to share their insights on harmonizing established statistical practices with novel AI-driven tools. We will explore what embracing these trends means for professionals at various stages of their careers: - Junior Statisticians: How to effectively contribute to clinical trials while integrating new data types and technologies. - Senior Statisticians: Techniques for overseeing multiple projects that blend established methods with innovative approaches. - People Managers: Guidance on leading teams through change, fostering a culture of adaptability, and leveraging both established and emerging tools for decision-making. BSLC is a collective of senior biopharmaceutical statistics leaders dedicated to improving patient outcomes through strategic collaboration. Comprised of 16 senior representatives from the statistical and biometrics departments of leading biopharma companies, we serve as a think tank driving initiatives that benefit biopharma statisticians and the broader industry.

2 Presentations

1:30 PM - 2:45 PM
Co-authors: Karin Bowen (AstraZeneca)
1:30 PM - 2:45 PM
Co-authors: Jared Christensen (Pfizer Research)

Discussants

Pandurang Kulkarni (Eli Lilly and Company)
Jared Christensen (Pfizer Research)
Karin Bowen (AstraZeneca)
Ivan Chan (Bristol Myers Squibb)
↑